Author Claim Review

 Quick Explanation Copied

 Long Explanation

Profile & Citation Metrics

Brandon J. Mannion (ORCID 0000-0002-1149-3790) shows an h-index of 18 with 46 works and ~5,272 citations (OpenAlex) versus 35 papers/2,372 citations (Semantic Scholar record) — a discrepancy typical of author-name disambiguation and consortium-paper attribution. His citation trajectory is strongly upward: from ~25 citations (2016) to a peak of ~947 (2024), driven largely by ENCODE III (Nature 2020, 2,380 citations) where he is one of hundreds of co-authors ENCODE III Nature 2020.

Scientific Strength: Lead Work

His most probative first-author-type contribution is the 2025 Nature Communications hidden-enhancers study: retrospective VISTA analysis (1,272 enhancers; 285 hidden, 14%) plus unbiased tiling of Gli3 and Smad3/Smad6 (63/281 tiles active; 26% of enhancer-tissue observations hidden), followed by a 303 kb CRISPR deletion showing redundant buffering Hidden enhancers via unbiased in vivo testing. This demonstrates conceptual courage: directly challenging chromatin-mark-based enhancer prediction (the paradigm he helped build in ENCODE). Earlier first/co-authored work on enhancer redundancy (Nature 2018, 642 citations) and ultraconserved enhancers (Cell 2018, 190 citations) established developmental enhancer robustness as a field-shaping theme Ultraconserved enhancers Cell 2018.

Critical Assessment

Strengths: rigorous in vivo validation (enSERT LacZ, CRISPR deletions, sensitized genetic backgrounds), transparent limitations, declared non-conflicts, NIH/DOE-funded LBNL/Berlin-brand developmental genomics lineage. Blindspots: (1) citation metrics are inflated by mega-consortium authorship — independent scientific strength must rest on the smaller set of lead papers; (2) the 2025 study's own stated limitations include LacZ reporter false positives/negatives, bulk-tissue chromatin missing cell-type-specific marks, limited stages, and cross-species extrapolation Limitations and falsification criteria; (3) the redundant-buffering interpretation (digit bifurcation in 4/7 vs 2/3 embryos, small n) is underpowered for definitive effect-size claims — an acknowledged inferential leap. Confidence in this review: moderate-to-high for metrics and lead-paper quality; low for fine-grained per-author contribution weighting within consortia.

Deepen Author Review on BGPT Run AI Scientist Analysis

 BGPT Author Review

Scientific Quality

Solid mid-career researcher (h-index 18, ~5.3k citations) with genuinely important lead contributions (hidden enhancers, enhancer redundancy) published in top journals; however, the majority of citation mass derives from consortium mega-papers, so independent scientific impact is narrower than raw metrics suggest. No red flags of rigor or integrity found; the 2025 paper honestly reports its own limits.

Communication Quality

Papers show clear structure, quantitative reporting, and explicit limitation/falsification framing (unusual and commendable). As a consortium member his communication impact is diffuse; no independent evidence of broad-audience writing or science communication beyond primary literature.

Author Novelty

The hidden-enhancers study directly challenges the chromatin-mark-based enhancer discovery paradigm he helped construct — a conceptually courageous, field-relevant reframing. Enhancer redundancy/robustness work was also field-defining, though the core redundancy concept was anticipated by prior synthetic and evolutionary biology work.

Scientific Rigor

Uses orthogonal validation (retrospective VISTA + prospective tiling + CRISPR deletion), reports sample sizes (e.g., 4/7, 2/3 embryos), declares no competing interests, and pre-states falsification routes. Weaknesses: small-n deletion phenotypes, bulk-tissue chromatin resolution, LacZ assay limitations — all acknowledged by the author rather than hidden, which itself reflects rigor.